Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jun;3(6):630-5.
doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

Alexander Drilon  1 , Lu Wang, Adnan Hasanovic, Yoshiyuki Suehara, Doron Lipson, Phil Stephens, Jeffrey Ross, Vincent Miller, Michelle Ginsberg, Maureen F Zakowski, Mark G Kris, Marc Ladanyi, Naiyer Rizvi
Affiliations
Clinical Trial

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

Alexander Drilon et al. Cancer Discov. 2013 Jun.

Abstract

The discovery of RET fusions in lung cancers has uncovered a new therapeutic target for patients whose tumors harbor these changes. In an unselected population of non-small cell lung carcinomas (NSCLCs), RET fusions are present in 1% to 2% of cases. This incidence increases substantially, however, in never-smokers with lung adenocarcinomas that lack other known driver oncogenes. Although preclinical data provide experimental support for the use of RET inhibitors in the treatment of RET fusion-positive tumors, clinical data on response are lacking. We report preliminary data for the first three patients treated with the RET inhibitor cabozantinib on a prospective phase II trial for patients with RET fusion-positive NSCLCs (NCT01639508). Confirmed partial responses were observed in 2 patients, including one harboring a novel TRIM33-RET fusion. A third patient with a KIF5B-RET fusion has had prolonged stable disease approaching 8 months (31 weeks). All three patients remain progression-free on treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

D. Lipson is employed as Director of Foundation Medicine and has ownership interest (including patents) in the same. P. Stephens has ownership interest (including patents) in Foundation Medicine. J. Ross is employed as Medical Director of Foundation Medicine, has received a commercial research grant from Foundation Medicine, and has ownership interest (including patents) in the same. V. Miller is employed as Senior Vice President, Clinical Development, at Foundation Medicine and has ownership interest (including patents) in the same. M.G. Kris is a consultant/advisory board member of Pfizer, Inc. No potential conflicts of interest were disclosed by the other authors.

Figures

Figure 1
Figure 1
A, photomicrograph of a supraclavicular lymph node biopsy showing a lung adenocarcinoma with papillary morphology. B, a positive RET FISH break-apart test. Split green and red signals indicate the presence of a RET fusion. Probes were designed as previously published (13). C, the presumptive t(1;10)(p13;q11.2) translocation places TRIM33 exons 1 to 14 upstream of RET exons 12 to 18, generating an in-frame TRIM33–RET fusion gene.
Figure 2
Figure 2
A1, baseline chest CT of the first patient with TRIM33–RET showing paramediastinal and pleural-based nodularities in the left upper lobe. A2, repeat imaging after 4 weeks of therapy revealing the disappearance of paramediastinal disease and a significant reduction of pleural-based disease. B1, chest CT of the second RET fusion-positive patient showing 2 nodules in the right lower lobe. B2, decrease in both size and solid components of both lesions at 4 weeks. C1, baseline imaging of the third patient with KIF5B–RET showing small bilateral pulmonary nodules. C2, stable disease at 4 weeks. All responses have been confirmed at 12 weeks and have since been maintained clinically and radiographically. Baseline disease burden was relatively low for all 3 cases.
Figure 3
Figure 3
RET fusions reported in the literature are depicted including major recurrent KIF5B–RET fusions, CCDC6–RET, NCOA4–RET (–16, 20), and the novel TRIM33–RET. All fusions encode an intact RET kinase domain as shown in blue. Regions encoding coiled-coil domains that mediate dimerization are shown in red (the N-terminal NCOA4 coiled-coil domain is not well defined). Part of the RET transmembrane domain encoded by RET exon 11 is shown in purple.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–24. - PMC - PubMed
    1. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863–70. - PMC - PubMed
    1. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4–ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275–83. - PMC - PubMed
    1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4–ALK fusion gene in non–small-cell lung cancer. Nature. 2007;448:561–6. - PubMed
    1. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–203. - PubMed

Publication types

MeSH terms

Associated data